Haematologica 2020 Jan 30
Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data.
Raskovalova T, Deegan PB, Mistry PK, Pavlova E, Yang R, Zimran A, Berger J, Bourgne C, Pereira B, Labarère J, Berger MG
Chitotriosidase activity and CCL18 concentration are interchangeably used for monitoring Gaucher disease (GD) activity, together with clinical assessm ...
Read More
Source: PubMed
Eur J Pain 2020 Jan 29
Dual-action ambroxol in treatment of chronic pain in Gaucher Disease.
Pawlinski L, Krawczyk M, Fiema M, Tobor E, Kiec-Wilk B
A significant number of patients with Gaucher disease (GD) suffer from chronic or acute pain that reduces their quality of life. A mutation in lysosom ...
Read More
Source: PubMed
Mol Genet Metab Rep
Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1.
Vu L, Cox GF, Ibrahim J, Peterschmitt MJ, Ross L, Thibault N, Turpault S
Eliglustat is an oral glucosylceramide synthase inhibitor indicated for the long-term treatment of adults with Gaucher disease type 1 and CYP2D6 exten ...
Read More
Source: PubMed
Diagnostics (Basel)
Mass Spectrometry Evaluation of Biomarkers in the Vitreous Fluid in Gaucher Disease Type 3 with Disease Progression Despite Long-Term Treatment.
Mhanni A, Boutin M, Stockl F, Johnston J, Barnes J, Duerksen D, Zimmer L, Auray-Blais C, Rockman-Greenberg C
Intraocular lesions have been infrequently reported in patients with Gaucher disease type 3 (GD3). We previously reported siblings with GD3 who respon ...
Read More
Source: PubMed
Am. J. Hematol. 2020 Jan 28
Semaphorin 7A: a novel marker of disease activity in Gaucher disease.
Franco M, Reihani N, Dupuis L, Collec E, de Villemeur TB, de Person M, Moussa F, Berger MG, Belmatoug N, Le Van Kim C
Gaucher disease (GD) is a recessively inherited lysosomal storage disorder in which sphingolipids accumulates in the macrophages that transform into G ...
Read More
Source: PubMed
Haematologica 2020 Jan 30
Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data.
Raskovalova T, Deegan PB, Mistry PK, Pavlova E, Yang R, Zimran A, Berger J, Bourgne C, Pereira B, Labarère J, Berger MG
Chitotriosidase activity and CCL18 concentration are interchangeably used for monitoring Gaucher disease (GD) activity, together with clinical assessm ...
Read More
Source: PubMed
Eur J Pain 2020 Jan 29
Dual-action ambroxol in treatment of chronic pain in Gaucher Disease.
Pawlinski L, Krawczyk M, Fiema M, Tobor E, Kiec-Wilk B
A significant number of patients with Gaucher disease (GD) suffer from chronic or acute pain that reduces their quality of life. A mutation in lysosom ...
Read More
Source: PubMed
Mol Genet Metab Rep
Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1.
Vu L, Cox GF, Ibrahim J, Peterschmitt MJ, Ross L, Thibault N, Turpault S
Eliglustat is an oral glucosylceramide synthase inhibitor indicated for the long-term treatment of adults with Gaucher disease type 1 and CYP2D6 exten ...
Read More
Source: PubMed
Diagnostics (Basel)
Mass Spectrometry Evaluation of Biomarkers in the Vitreous Fluid in Gaucher Disease Type 3 with Disease Progression Despite Long-Term Treatment.
Mhanni A, Boutin M, Stockl F, Johnston J, Barnes J, Duerksen D, Zimmer L, Auray-Blais C, Rockman-Greenberg C
Intraocular lesions have been infrequently reported in patients with Gaucher disease type 3 (GD3). We previously reported siblings with GD3 who respon ...
Read More
Source: PubMed
Am. J. Hematol. 2020 Jan 28
Semaphorin 7A: a novel marker of disease activity in Gaucher disease.
Franco M, Reihani N, Dupuis L, Collec E, de Villemeur TB, de Person M, Moussa F, Berger MG, Belmatoug N, Le Van Kim C
Gaucher disease (GD) is a recessively inherited lysosomal storage disorder in which sphingolipids accumulates in the macrophages that transform into G ...
Read More
Source: PubMed
Haematologica 2020 Jan 30
Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data.
Raskovalova T, Deegan PB, Mistry PK, Pavlova E, Yang R, Zimran A, Berger J, Bourgne C, Pereira B, Labarère J, Berger MG
Chitotriosidase activity and CCL18 concentration are interchangeably used for monitoring Gaucher disease (GD) activity, together with clinical assessm ...
Read More
Source: PubMed
Eur J Pain 2020 Jan 29
Dual-action ambroxol in treatment of chronic pain in Gaucher Disease.
Pawlinski L, Krawczyk M, Fiema M, Tobor E, Kiec-Wilk B
A significant number of patients with Gaucher disease (GD) suffer from chronic or acute pain that reduces their quality of life. A mutation in lysosom ...
Read More
Source: PubMed
Mol Genet Metab Rep
Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1.
Vu L, Cox GF, Ibrahim J, Peterschmitt MJ, Ross L, Thibault N, Turpault S
Eliglustat is an oral glucosylceramide synthase inhibitor indicated for the long-term treatment of adults with Gaucher disease type 1 and CYP2D6 exten ...
Read More
Source: PubMed
Diagnostics (Basel)
Mass Spectrometry Evaluation of Biomarkers in the Vitreous Fluid in Gaucher Disease Type 3 with Disease Progression Despite Long-Term Treatment.
Mhanni A, Boutin M, Stockl F, Johnston J, Barnes J, Duerksen D, Zimmer L, Auray-Blais C, Rockman-Greenberg C
Intraocular lesions have been infrequently reported in patients with Gaucher disease type 3 (GD3). We previously reported siblings with GD3 who respon ...
Read More
Source: PubMed
Am. J. Hematol. 2020 Jan 28
Semaphorin 7A: a novel marker of disease activity in Gaucher disease.
Franco M, Reihani N, Dupuis L, Collec E, de Villemeur TB, de Person M, Moussa F, Berger MG, Belmatoug N, Le Van Kim C
Gaucher disease (GD) is a recessively inherited lysosomal storage disorder in which sphingolipids accumulates in the macrophages that transform into G ...
Read More
Source: PubMed
Haematologica 2020 Jan 30
Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data.
Raskovalova T, Deegan PB, Mistry PK, Pavlova E, Yang R, Zimran A, Berger J, Bourgne C, Pereira B, Labarère J, Berger MG
Chitotriosidase activity and CCL18 concentration are interchangeably used for monitoring Gaucher disease (GD) activity, together with clinical assessm ...
Read More
Source: PubMed
Eur J Pain 2020 Jan 29
Dual-action ambroxol in treatment of chronic pain in Gaucher Disease.
Pawlinski L, Krawczyk M, Fiema M, Tobor E, Kiec-Wilk B
A significant number of patients with Gaucher disease (GD) suffer from chronic or acute pain that reduces their quality of life. A mutation in lysosom ...
Read More
Source: PubMed
Mol Genet Metab Rep
Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1.
Vu L, Cox GF, Ibrahim J, Peterschmitt MJ, Ross L, Thibault N, Turpault S
Eliglustat is an oral glucosylceramide synthase inhibitor indicated for the long-term treatment of adults with Gaucher disease type 1 and CYP2D6 exten ...
Read More
Source: PubMed
Diagnostics (Basel)
Mass Spectrometry Evaluation of Biomarkers in the Vitreous Fluid in Gaucher Disease Type 3 with Disease Progression Despite Long-Term Treatment.
Mhanni A, Boutin M, Stockl F, Johnston J, Barnes J, Duerksen D, Zimmer L, Auray-Blais C, Rockman-Greenberg C
Intraocular lesions have been infrequently reported in patients with Gaucher disease type 3 (GD3). We previously reported siblings with GD3 who respon ...
Read More
Source: PubMed
Am. J. Hematol. 2020 Jan 28
Semaphorin 7A: a novel marker of disease activity in Gaucher disease.
Franco M, Reihani N, Dupuis L, Collec E, de Villemeur TB, de Person M, Moussa F, Berger MG, Belmatoug N, Le Van Kim C
Gaucher disease (GD) is a recessively inherited lysosomal storage disorder in which sphingolipids accumulates in the macrophages that transform into G ...
Read More
Source: PubMed
